Clinical Trial Update: A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma [Phase 2]

View source ↗

Summary

A Phase II trial evaluating cetuximab in combination with irinotecan in EGFR-detectable metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Camptosar (irinotecan)
• ERBITUX (cetuximab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Colorectal Carcinoma | Phase 2 | Status: COMPLETED